Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.62 -1.21 (-2.48%)
Streaming Delayed Price Updated: 9:42 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
News headline image
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox ↗
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV. 
Via Benzinga
News headline image
1 big new Green Flag for CRISPR Therapeutics' Stock ↗
Via The Motley Fool
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
My Top 5 Stocks to Buy in Early 2025 ↗
Via The Motley Fool
News headline image
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia ↗
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares. 
Via Benzinga
Topics Artificial Intelligence
News headline image
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗
Via The Motley Fool
News headline image
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market. 
Via MarketBeat
News headline image
My 10 Top Stocks to Buy to Start the New Year Off Right ↗
Via The Motley Fool
News headline image
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗
Via The Motley Fool
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
3 Mid-Cap Stocks That Could Take Off in 2025 ↗
Via The Motley Fool
News headline image
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
News headline image
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? ↗
Via The Motley Fool
News headline image
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
News headline image
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗
Via The Motley Fool
News headline image
3 Things You Need to Know if You Buy CRISPR Therapeutics Today ↗
Via The Motley Fool
News headline image
2 Biotech Stocks to Buy Hand Over Fist in December ↗
Via The Motley Fool
News headline image
3 of the Best Growth Stocks You Can Buy for Less than $100 ↗
Via The Motley Fool
News headline image
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65% ↗
Via The Motley Fool
News headline image
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments ↗
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
News headline image
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.